{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T01:33:19Z","timestamp":1795138399752,"version":"4.10.3"},"reference-count":312,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.fjurol.2024.102717","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T03:57:57Z","timestamp":1732247877000},"page":"102717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2024\u20132026: Prostate cancer\u00a0\u2013\u00a0Diagnosis and management of localised disease"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-2152","authenticated-orcid":false,"given":"Guillaume","family":"Ploussard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Baboudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Fiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5409-2911","authenticated-orcid":false,"given":"Jonathan","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9573-2938","authenticated-orcid":false,"given":"Charles","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Rozet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-0082","authenticated-orcid":false,"given":"Arthur","family":"Peyrottes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eble","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1000","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.annonc.2020.02.009","article-title":"European cancer mortality predictions for the year 2020 with a focus on prostate cancer","volume":"31","author":"Carioli","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102717_bib1005","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.purol.2015.04.011","article-title":"[Prostate cancer incidence and mortality trends in France from 1980 to 2011]","volume":"25","author":"Grosclaude","year":"2015","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ijc.32287","article-title":"Endocrine disrupting-chemicals and biochemical recurrence of prostate cancer after prostatectomy: a cohort study in Guadeloupe (French West Indies)","volume":"146","author":"Brureau","year":"2020","journal-title":"Int J Cancer"},{"issue":"21","key":"10.1016\/j.fjurol.2024.102717_bib1015","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2009.27.2153","article-title":"Chlordecone exposure and risk of prostate cancer","volume":"28","author":"Multigner","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102717_bib1020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1186\/s12889-015-2260-x","article-title":"Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada","volume":"15","author":"Blanc-Lapierre","year":"2015","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF03346748","article-title":"Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis","volume":"36","author":"Esposito","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib1030","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s10552-015-0654-9","article-title":"The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium","volume":"26","author":"Davies","year":"2015","journal-title":"Cancer Causes Control"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102717_bib1035","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1158\/1055-9965.EPI-14-0795","article-title":"Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study","volume":"23","author":"Vidal","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102717_bib1040","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.urolonc.2020.04.008","article-title":"Testosterone replacement therapy (TRT) and prostate cancer: an updated systematic review with a focus on previous or active localized prostate cancer","volume":"38","author":"Lenfant","year":"2020","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2008.864","article-title":"Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"301","author":"Lippman","year":"2009","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib1050","first-page":"1208","article-title":"Using medicare claims to examine long-term prostate cancer risk of finasteride in the prostate cancer prevention trial","volume":"110","author":"Unger","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.fjurol.2024.102717_bib1055","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1060","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1065","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2014.30","article-title":"Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease","volume":"110","author":"Leongamornlert","year":"2014","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1070","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00439-012-1229-4","article-title":"HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)","volume":"132","author":"Xu","year":"2013","journal-title":"Hum Genet"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1075","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2018.11.015","article-title":"Homeobox B13 G84E mutation and prostate cancer risk","volume":"75","author":"Nyberg","year":"2019","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102717_bib1080","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/pros.23795","article-title":"The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis","volume":"79","author":"Oh","year":"2019","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1085","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1158\/0008-5472.CAN-19-1840","article-title":"Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness","volume":"80","author":"Patel","year":"2020","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1090","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.purol.2021.12.007","article-title":"[DNA repair gene alterations testing in prostate cancer: a practical update by the prostate cancer committee of the French Association of Urology]","volume":"32","author":"Ploussard","year":"2022","journal-title":"Prog Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1095","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1100","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1105","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1110","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/jnci\/djab147","article-title":"Breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers using Polygenic Risk Scores","volume":"114","author":"Barnes","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib1120","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.annonc.2020.06.025","article-title":"Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening","volume":"31","author":"Segal","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2018.08.026","article-title":"Mutational profile of aggressive, localised prostate cancer from African Caribbean men versus European ancestry men","volume":"75","author":"Tonon","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1135","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the european randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.eururo.2012.11.041","article-title":"Health-related quality of life in the Finnish trial of screening for prostate cancer","volume":"65","author":"Booth","year":"2014","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102717_bib1150","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3109\/0284186X.2013.802837","article-title":"Effects of prostate cancer screening on health-related quality of life: results of the Finnish arm of the European randomized screening trial (ERSPC)","volume":"52","author":"Vasarainen","year":"2013","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102717_bib1155","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa1201637","article-title":"Quality-of-life effects of prostate-specific antigen screening","volume":"367","author":"Heijnsdijk","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1160","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.euo.2023.09.008","article-title":"Digital rectal examination is not a useful screening test for prostate cancer","volume":"6","author":"Krilaviciute","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1165","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.euo.2023.12.005","article-title":"Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Matsukawa","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1170","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2019.04.033","article-title":"Structured population-based prostate-specific antigen screening for prostate cancer: the European Association of Urology Position in 2019","volume":"76","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1175","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pros.22925","article-title":"Prostate cancer risk prediction based on complete prostate cancer family history","volume":"75","author":"Albright","year":"2015","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102717_bib1180","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/pros.21314","article-title":"Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer","volume":"71","author":"Chornokur","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.fjurol.2024.102717_bib1185","article-title":"Defining the impact of family history on detection of high-grade prostate cancer in a large multi-institutional cohort","author":"Clements","year":"2021","journal-title":"Eur Urol"},{"issue":"9959","key":"10.1016\/j.fjurol.2024.102717_bib1190","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schroder","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1195","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.euo.2021.09.001","article-title":"Prostate cancer screening with magnetic resonance imaging: results from the second round of the goteborg prostate cancer screening 2 Trial","volume":"5","author":"Wallstrom","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1200","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2006.06.9351","article-title":"Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years","volume":"25","author":"Lilja","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102717_bib1205","doi-asserted-by":"crossref","first-page":"f2023","DOI":"10.1136\/bmj.f2023","article-title":"Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study","volume":"346","author":"Vickers","year":"2013","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.fjurol.2024.102717_bib1210","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2016.66.7527","article-title":"Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer","volume":"34","author":"Preston","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1215","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.euo.2021.06.006","article-title":"A European model for an organised risk-stratified early detection programme for prostate cancer","volume":"4","author":"Van Poppel","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102717_bib1220","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2024.04.030","article-title":"Risk-adjusted screening for prostate cancer-defining the low-risk group by data from the PROBASE Trial","author":"Krilaviciute","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1225","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2008.03.104","article-title":"The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam","volume":"54","author":"Gosselaar","year":"2008","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.fjurol.2024.102717_bib1230","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level\u00a0<\u00a0or\u00a0=\u00a04.0\u00a0ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102717_bib1235","doi-asserted-by":"crossref","first-page":"829","DOI":"10.6004\/jnccn.2018.7278","article-title":"Digital rectal examination remains a key prognostic tool for prostate cancer: a national cancer database review","volume":"17","author":"Borkenhagen","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1240","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/pros.20286","article-title":"Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden","volume":"65","author":"Bruun","year":"2005","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1245","doi-asserted-by":"crossref","first-page":"e1919284","DOI":"10.1001\/jamanetworkopen.2019.19284","volume":"3","author":"Kovac","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1250","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41391-017-0024-7","article-title":"Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer","volume":"21","author":"Nordstrom","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1255","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/s41391-021-00373-w","article-title":"Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models","volume":"24","author":"Stavrinides","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"17","key":"10.1016\/j.fjurol.2024.102717_bib1260","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.3390\/cancers13174251","article-title":"Biomarker in active surveillance for prostate cancer: a systematic review","volume":"13","author":"Manceau","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1265","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.euf.2017.02.017","article-title":"Prognostic biomarkers used for localised prostate cancer management: a systematic review","volume":"4","author":"Lamy","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102717_bib1270","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1464-410X.2012.11072.x","article-title":"Role of transrectal ultrasonography (TRUS) in focal therapy of prostate cancer: report from a Consensus Panel","volume":"110","author":"Smeenge","year":"2012","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1275","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1470-2045(22)00016-X","article-title":"Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study","volume":"23","author":"Grey","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1280","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.euo.2018.10.001","article-title":"Comparison of the diagnostic accuracy of micro-ultrasound and magnetic resonance imaging\/ultrasound fusion targeted biopsies for the diagnosis of clinically significant prostate cancer","volume":"2","author":"Lughezzani","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1285","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.juro.2015.12.093","article-title":"Assessing cancer risk on novel 29\u00a0MHz micro-ultrasound images of the prostate: creation of the micro-ultrasound protocol for prostate risk identification","volume":"196","author":"Ghai","year":"2016","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1290","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1097\/JU.0000000000001639","article-title":"Micro-ultrasound-guided vs. multiparametric magnetic resonance imaging-targeted biopsy in the detection of prostate cancer: a systematic review and meta-analysis","volume":"205","author":"Sountoulides","year":"2021","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1295","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/bju.15635","article-title":"A non-inferiority comparative analysis of micro-ultrasonography and MRI-targeted biopsy in men at risk of prostate cancer","volume":"129","author":"Hofbauer","year":"2022","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1300","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1305","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JU.0000000000000617","article-title":"Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer","volume":"203","author":"Bjurlin","year":"2020","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1310","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.eururo.2019.05.029","article-title":"High diagnostic performance of short magnetic resonance imaging protocols for prostate cancer detection in biopsy-naive men: the next step in magnetic resonance imaging accessibility","volume":"76","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2214\/AJR.20.24268","article-title":"PI-RADS Committee position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review","volume":"216","author":"Schoots","year":"2021","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1320","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2019.06.023","article-title":"Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis","volume":"77","author":"Drost","year":"2020","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1325","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1148\/radiol.2482070157","article-title":"Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis","volume":"248","author":"Tamada","year":"2008","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1330","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1148\/radiol.10100667","article-title":"Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?","volume":"258","author":"Turkbey","year":"2011","journal-title":"Radiology"},{"issue":"19","key":"10.1016\/j.fjurol.2024.102717_bib1335","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1340","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamaoncol.2020.7589","article-title":"Comparison of multiparametric magnetic resonance imaging-targeted biopsy with systematic transrectal ultrasonography biopsy for biopsy-naive men at risk for prostate cancer: a phase 3 randomized clinical trial","volume":"7","author":"Klotz","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1345","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study","volume":"20","author":"Rouviere","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1350","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102717_bib1355","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstrom","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102717_bib1360","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1365","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMc1807507","article-title":"MRI-targeted biopsy for prostate-cancer diagnosis","volume":"379","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1370","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bju.15277","article-title":"Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation","volume":"127","author":"Schoots","year":"2021","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1375","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1380","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1385","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.purol.2020.10.003","article-title":"[Short recommendations from the CIAFU: interest of the urine bacterial culture performed before endo-rectal prostate biopsy]","volume":"31","author":"Bruyere","year":"2021","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1390","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.acvd.2018.10.004","volume":"112","author":"Godier","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.fjurol.2024.102717_bib1395","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2016.12.011","article-title":"Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches","volume":"104","author":"Roberts","year":"2017","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1400","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.juro.2014.07.086","article-title":"Prosbiotate: a multicenter, prospective analysis of infectious complications after prostate biopsy","volume":"193","author":"Bruyere","year":"2015","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102717_bib1405","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1473-3099(22)00373-5","article-title":"Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial","volume":"22","author":"Jacewicz","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1410","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/pcan.2017.13","article-title":"Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach","volume":"20","author":"Bass","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1415","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.prnil.2021.05.003","article-title":"Topical antiseptic at time of transrectal ultrasound prostate biopsy is associated with fewer severe clinical infections and improves antibiotic stewardship","volume":"9","author":"Ramedani","year":"2021","journal-title":"Prostate Int"},{"key":"10.1016\/j.fjurol.2024.102717_bib1420","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.urology.2020.06.005","article-title":"A systematic review and meta-analysis of methods used to reduce infectious complications following transrectal prostate biopsy","volume":"144","author":"Jazayeri","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.fjurol.2024.102717_bib1425","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2024.01.019","article-title":"Transperineal versus transrectal magnetic resonance imaging-targeted biopsies for prostate cancer diagnosis: final results of the randomized PERFECT trial (CCAFU-PR1)","author":"Ploussard","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1430","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000003788","article-title":"Complications following transrectal and transperineal prostate biopsy: results of the ProBE-PC randomized clinical trial","volume":"211","author":"Mian","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1435","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","article-title":"Transperineal versus transrectal magnetic resonance imaging-targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial","volume":"86","author":"Hu","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1440","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9010225","article-title":"Assessment of the minimal targeted biopsy core number per MRI lesion for improving prostate cancer grading prediction","volume":"9","author":"Ploussard","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1445","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2019.04.008","article-title":"Role of core number and location in targeted magnetic resonance imaging-ultrasound fusion prostate biopsy","volume":"76","author":"Lu","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1450","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/JU.0000000000000527","article-title":"Minimum magnetic resonance imaging-ultrasound fusion targeted biopsy cores needed for prostate cancer detection: multivariable retrospective, lesion based analyses of patients treated with radical prostatectomy","volume":"203","author":"Leyh-Bannurah","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1455","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.euo.2022.08.005","article-title":"Detection of clinically significant prostate cancer using targeted biopsy with four cores versus target saturation biopsy with nine cores in transperineal prostate fusion biopsy: a prospective randomized trial","volume":"6","author":"Saner","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1460","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2018.11.040","article-title":"The FUTURE Trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies","volume":"75","author":"Wegelin","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102717_bib1465","article-title":"Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis","author":"Bass","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"16","key":"10.1016\/j.fjurol.2024.102717_bib1470","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.purol.2020.09.012","article-title":"What to expect from a non-suspicious prostate MRI? A review","volume":"30","author":"Fiard","year":"2020","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1475","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/JU.0000000000001414","article-title":"Negative prebiopsy magnetic resonance imaging and risk of significant prostate cancer: baseline and long-term follow-up results","volume":"205","author":"Buisset","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1480","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/JU.0000000000000757","article-title":"Predictive factors of missed clinically significant prostate cancers in men with negative magnetic resonance imaging: a systematic review and meta-analysis","volume":"204","author":"Pagniez","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1485","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.purol.2020.09.025","article-title":"Should we perform systematic biopsies in case of suspicious MRI for prostate cancer in 2020? A review of literature","volume":"31","author":"Vesval","year":"2021","journal-title":"Prog Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1490","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/bju.15568","article-title":"The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia","volume":"129","author":"Morote","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102717_bib1495","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2023.12.015","article-title":"Transperineal versus transrectal magnetic resonance imaging-targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT Randomized Trial","author":"Hu","year":"2024","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102717_bib1500","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma","volume":"44","author":"van Leenders","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1505","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5858\/arpa.2020-0015-RA","article-title":"The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer","volume":"145","author":"Epstein","year":"2021","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1510","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1515","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the Gleason Score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"issue":"Suppl. 3","key":"10.1016\/j.fjurol.2024.102717_bib1520","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bju.15556","article-title":"The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade","volume":"128","author":"Hennes","year":"2021","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1525","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2019.07.051","article-title":"Improved prostate cancer biopsy grading by incorporation of invasive cribriform and intraductal carcinoma in the 2014 grade groups","volume":"77","author":"van Leenders","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1530","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eururo.2023.03.014","article-title":"Impact of epithelial histological types, subtypes, and growth patterns on oncological outcomes for patients with nonmetastatic prostate cancer treated with curative intent: a systematic review","volume":"84","author":"Marra","year":"2023","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102717_bib1535","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/PAS.0b013e3182217b79","article-title":"Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings","volume":"35","author":"Karram","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1540","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.euo.2018.03.013","article-title":"Features and prognostic significance of intraductal carcinoma of the prostate","volume":"1","author":"Montironi","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"S1","key":"10.1016\/j.fjurol.2024.102717_bib1545","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/modpathol.2017.138","article-title":"High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate","volume":"31","author":"Zhou","year":"2018","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1550","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/modpathol.2010.160","article-title":"International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 4: seminal vesicles and lymph nodes","volume":"24","author":"Berney","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1016\/j.fjurol.2024.102717_bib1555","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.humpath.2022.06.004","article-title":"Morphologic spectrum of treatment-related changes in prostate tissue and prostate cancer: an updated review","volume":"127","author":"Collins","year":"2022","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1560","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/PAP.0b013e318220f5b1","article-title":"Treatment effects in the prostate including those associated with traditional and emerging therapies","volume":"18","author":"Evans","year":"2011","journal-title":"Adv Anat Pathol"},{"issue":"18","key":"10.1016\/j.fjurol.2024.102717_bib1565","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djm117","article-title":"Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial","volume":"99","author":"Lucia","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1570","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5858\/2007-131-360-DOPCAT","article-title":"Diagnosis of prostatic carcinoma after therapy","volume":"131","author":"Bostwick","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1575","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2018.01.043","article-title":"Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer","volume":"74","author":"Mahal","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1580","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.eururo.2019.09.027","article-title":"Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study","volume":"77","author":"Zelic","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1585","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of presalvage radiotherapy psa levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1590","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","article-title":"Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis","volume":"70","author":"de Rooij","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1595","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2214\/ajr.166.4.8610561","article-title":"Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology","volume":"166","author":"Jager","year":"1996","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1600","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1148\/radiol.2372041724","article-title":"Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers","volume":"237","author":"Futterer","year":"2005","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102717_bib1605","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00330-012-2475-5","article-title":"Prediction of prostate cancer extraPCasular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI","volume":"22","author":"Bloch","year":"2012","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1610","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1148\/radiol.2321031086","article-title":"Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extraPCasular extension","volume":"232","author":"Wang","year":"2004","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1615","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1148\/radiol.2018181278","article-title":"A grading system for the assessment of risk of extraprostatic extension of prostate cancer at multiparametric MRI","volume":"290","author":"Mehralivand","year":"2019","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1620","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2012.11324.x","article-title":"An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011","volume":"111","author":"Eifler","year":"2013","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1625","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2011.10.044","article-title":"Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores","volume":"61","author":"Briganti","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1630","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","article-title":"A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies","volume":"75","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1635","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"Hovels","year":"2008","journal-title":"Clin Radiol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1640","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12149-012-0660-x","article-title":"The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006\u20132009) nationwide survey","volume":"27","author":"Minamimoto","year":"2013","journal-title":"Ann Nucl Med"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1645","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.09.039","article-title":"Utility of choline positron emission tomography\/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis","volume":"63","author":"Evangelista","year":"2013","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1650","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/21681805.2021.1914720","volume":"55","author":"Puterman","year":"2021","journal-title":"Scand J Urol"},{"issue":"10231","key":"10.1016\/j.fjurol.2024.102717_bib1655","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib1660","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1665","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with (18)F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1670","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.juro.2015.12.025","article-title":"Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer","volume":"195","author":"Maurer","year":"2016","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1675","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00259-020-04974-w","article-title":"Pelvic lymph-node staging with (18)F-DCFPyL PET\/CT prior to extended pelvic lymph-node dissection in primary prostate cancer \u2013 the SALT trial","volume":"48","author":"Jansen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1680","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bju.15134","article-title":"Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET\/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer","volume":"127","author":"Franklin","year":"2021","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1685","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2014.05.011","article-title":"More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer","volume":"67","author":"Abdollah","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1690","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/iju.12184","article-title":"Sentinel lymph node dissection in more than 1200 prostate cancer cases: rate and prediction of lymph node involvement depending on preoperative tumor characteristics","volume":"21","author":"Winter","year":"2014","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1695","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.eururo.2012.06.057","article-title":"Mapping of pelvic lymph node metastases in prostate cancer","volume":"63","author":"Joniau","year":"2013","journal-title":"Eur Urol"},{"issue":"6 Pt 1","key":"10.1016\/j.fjurol.2024.102717_bib1700","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1097\/01.ju.0000123981.03084.06","article-title":"Baseline staging of newly diagnosed prostate cancer: a summary of the literature","volume":"171","author":"Abuzallouf","year":"2004","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1705","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00259-013-2532-6","article-title":"Whole-body SPECT\/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients","volume":"41","author":"Palmedo","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib1710","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.2967\/jnumed.123.265916","article-title":"Do bone scans overstage disease compared with PSMA PET at initial staging? An international multicenter retrospective study with masked independent readers","volume":"64","author":"Hope","year":"2023","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1715","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/bju.12599","article-title":"Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)\/computed tomography (CT) and [(18) F]NaF PET\/CT","volume":"114","author":"Poulsen","year":"2014","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib1720","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","article-title":"Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis","volume":"43","author":"Shen","year":"2014","journal-title":"Skeletal Radiol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1725","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.euo.2020.06.012","volume":"4","author":"Anttinen","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102717_bib1730","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s00330-010-1879-3","article-title":"Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa)","volume":"20","author":"Lecouvet","year":"2010","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1735","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00256-009-0789-4","article-title":"Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma","volume":"39","author":"Gutzeit","year":"2010","journal-title":"Skeletal Radiol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1740","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0090-4295(90)80184-O","article-title":"Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up","volume":"36","author":"Graversen","year":"1990","journal-title":"Urology"},{"issue":"24","key":"10.1016\/j.fjurol.2024.102717_bib1745","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","article-title":"Radical prostatectomy or watchful waiting in prostate cancer\u00a0\u2013\u00a029-year follow-up","volume":"379","author":"Bill-Axelson","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1750","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","article-title":"Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT)","volume":"77","author":"Wilt","year":"2020","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.fjurol.2024.102717_bib1755","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fjurol.2024.102717_bib1760","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1765","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/bju.14987","article-title":"The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression","volume":"125","author":"Bryant","year":"2020","journal-title":"BJU Int"},{"issue":"17","key":"10.1016\/j.fjurol.2024.102717_bib1770","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1775","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1780","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/JU.0000000000000713","article-title":"Long-term outcomes of active surveillance for prostate cancer: the Memorial Sloan Kettering Cancer Center Experience","volume":"203","author":"Carlsson","year":"2020","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1785","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/JU.0000000000000742","article-title":"Risk of metastasis in men with grade group 2 prostate cancer managed with active surveillance at a tertiary cancer center","volume":"203","author":"Carlsson","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102717_bib1790","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1795","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eururo.2012.08.066","article-title":"Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial","volume":"63","author":"Godtman","year":"2013","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1800","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2012.11.005","article-title":"Active surveillance for low-risk prostate cancer worldwide: the PRIAS study","volume":"63","author":"Bul","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1805","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an International Collaborative Study (DETECTIVE Study)","volume":"76","author":"Lam","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1810","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.euo.2023.02.014","article-title":"Is active surveillance an option for the management of men with low-grade prostate cancer and a positive family history? Results from a large, single-institution series","volume":"6","author":"Leni","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1815","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","article-title":"Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression","volume":"5","author":"Baboudjian","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102717_bib1820","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2019.10.039","article-title":"Impact of MRI and targeted biopsies on eligibility and disease reclassification in MRI-positive candidates for active surveillance on systematic biopsies","volume":"137","author":"Ploussard","year":"2020","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1825","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00345-023-04353-8","article-title":"Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approach","volume":"41","author":"Baboudjian","year":"2023","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1830","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","article-title":"Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up","volume":"77","author":"Klotz","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1835","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.eururo.2019.02.035","article-title":"The value of an extensive transrectal repeat biopsy with anterior sampling in men on active surveillance for low-risk prostate cancer: a comparison from the randomised study of active monitoring in Sweden (SAMS)","volume":"76","author":"Bratt","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1840","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","article-title":"Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE Recommendations\u00a0\u2013\u00a0A report of a European School of Oncology Task Force","volume":"71","author":"Moore","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1845","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.euo.2020.09.002","article-title":"Can the use of serial multiparametric magnetic resonance imaging during active surveillance of prostate cancer avoid the need for prostate biopsies\u00a0\u2013\u00a0A systematic diagnostic test accuracy review","volume":"4","author":"Hettiarachchi","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1850","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis","volume":"80","author":"Rajwa","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1855","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.eururo.2021.12.007","article-title":"Systematic review of active surveillance for clinically localised prostate cancer to develop recommendations regarding inclusion of intermediate-risk disease, biopsy characteristics at inclusion and monitoring, and surveillance repeat biopsy strategy","volume":"81","author":"Willemse","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1860","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JU.0000000000001339","article-title":"The clinical significance of multiple negative surveillance prostate biopsies for men on active surveillance-does cancer vanish or simply hide?","volume":"205","author":"Chu","year":"2021","journal-title":"J Urol"},{"issue":"17","key":"10.1016\/j.fjurol.2024.102717_bib1865","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2009.25.7311","article-title":"Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program","volume":"28","author":"Ross","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1870","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/JU.0000000000003461","article-title":"Identifying men who can remain on active surveillance despite biopsy reclassification to Grade Group 2 Prostate Cancer","volume":"210","author":"Baraban","year":"2023","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib1875","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S1470-2045(13)70366-8","article-title":"Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study","volume":"14","author":"Ornish","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1880","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cct.2014.05.002","article-title":"A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance])","volume":"38","author":"Parsons","year":"2014","journal-title":"Contemp Clin Trials"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1885","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.euo.2023.10.010","article-title":"Nonsurgical interventions to prevent disease progression in prostate cancer patients on active surveillance: a systematic review and meta-analysis","volume":"7","author":"Matsukawa","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"9821","key":"10.1016\/j.fjurol.2024.102717_bib1890","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(11)61619-X","article-title":"Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial","volume":"379","author":"Fleshner","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1895","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euf.2022.12.002","article-title":"A phase 2, double-blind, randomized controlled trial of PROSTVAC in prostate cancer patients on active surveillance","volume":"9","author":"Parsons","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102717_bib1900","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2022.1641","article-title":"Enzalutamide monotherapy vs. active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT Randomized Clinical Trial","volume":"8","author":"Shore","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102717_bib1905","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"370","author":"Bill-Axelson","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1910","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.critrevonc.2009.09.005","article-title":"Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults","volume":"73","author":"Droz","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10049","key":"10.1016\/j.fjurol.2024.102717_bib1915","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(16)30592-X","article-title":"Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study","volume":"388","author":"Yaxley","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1920","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00345-021-03878-0","article-title":"Annual nationwide analysis of costs and post-operative outcomes after radical prostatectomy according to the surgical approach (open, laparoscopic, and robotic)","volume":"40","author":"Ploussard","year":"2022","journal-title":"World J Urol"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102717_bib1925","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S1470-2045(18)30357-7","article-title":"Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study","volume":"19","author":"Coughlin","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib1930","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/bju.14062","article-title":"Laparoscopic and robot-assisted vs. open radical prostatectomy for the treatment of localized prostate cancer: a Cochrane systematic review","volume":"121","author":"Ilic","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.fjurol.2024.102717_bib1935","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2020.06.009","article-title":"One-day prehabilitation program before robotic radical prostatectomy in daily practice: routine feasibility and benefits for patients and hospitals","volume":"21","author":"Ploussard","year":"2020","journal-title":"Eur Urol Open Sci"},{"issue":"18","key":"10.1016\/j.fjurol.2024.102717_bib1940","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1002\/cncr.33061","article-title":"A combination of enhanced recovery after surgery and prehabilitation pathways improves perioperative outcomes and costs for robotic radical prostatectomy","volume":"126","author":"Ploussard","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1945","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.eururo.2015.11.004","article-title":"Preoperative pelvic floor muscle exercise and postprostatectomy incontinence: a systematic review and meta-analysis","volume":"69","author":"Chang","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1950","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.euf.2021.05.009","article-title":"Evaluation of oncological outcomes and data quality in studies assessing nerve-sparing versus non-nerve-sparing radical prostatectomy in nonmetastatic prostate cancer: a systematic review","volume":"8","author":"Moris","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib1955","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/JU.0000000000002205","article-title":"An algorithm to personalize nerve sparing in men with unilateral high-risk prostate cancer","volume":"207","author":"Martini","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102717_bib1960","first-page":"CD013641","article-title":"Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer","volume":"8","author":"Rosenberg","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib1965","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.eururo.2009.11.034","article-title":"Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy","volume":"57","author":"Rabbani","year":"2010","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1970","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.eururo.2007.04.020","article-title":"Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy","volume":"52","author":"Heidenreich","year":"2007","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1975","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.juro.2007.03.018","article-title":"Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%","volume":"178","author":"Touijer","year":"2007","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1980","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.eururo.2006.08.015","article-title":"Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer","volume":"50","author":"Briganti","year":"2006","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib1985","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","article-title":"The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review","volume":"72","author":"Fossati","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib1990","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.euo.2021.03.006","article-title":"Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial","volume":"4","author":"Touijer","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib1995","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","article-title":"Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 Trial","volume":"79","author":"Lestingi","year":"2021","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib2000","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.eururo.2009.01.036","article-title":"Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies","volume":"55","author":"Ficarra","year":"2009","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.fjurol.2024.102717_bib2005","first-page":"1654","article-title":"Functional outcomes after treatment for prostate cancer","volume":"368","author":"Resnick","year":"2013","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.fjurol.2024.102717_bib2010","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jnci\/dji313","article-title":"30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity","volume":"97","author":"Alibhai","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib2015","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2012.05.046","article-title":"Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy","volume":"62","author":"Ficarra","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2024.102717_bib2020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib2025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.brachy.2019.10.005","article-title":"Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy","volume":"19","author":"Tom","year":"2020","journal-title":"Brachytherapy"},{"key":"10.1016\/j.fjurol.2024.102717_bib2030","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.urology.2019.09.040","article-title":"Ten-year treatment outcomes of radical prostatectomy vs. external beam radiation therapy vs. brachytherapy for 1503 patients with intermediate-risk prostate cancer","volume":"136","author":"Goy","year":"2020","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib2035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.5114\/jcb.2017.70763","article-title":"Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy: results of two prospective randomized trials","volume":"9","author":"Merrick","year":"2017","journal-title":"J Contemp Brachytherapy"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2040","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijrobp.2017.09.050","article-title":"Prospective phase 2 trial of permanent seed implantation prostate brachytherapy for intermediate-risk localized prostate cancer: efficacy, toxicity, and quality of life outcomes","volume":"100","author":"Frank","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib2050","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bju.15739","article-title":"Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study)","volume":"130","author":"Lane","year":"2022","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.brachy.2017.10.001","article-title":"Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19\u00a0Gy high-dose-rate brachytherapy","volume":"17","author":"Mendez","year":"2018","journal-title":"Brachytherapy"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102717_bib2060","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.2017.75.9134","article-title":"Brachytherapy-based radiotherapy and radical prostatectomy are associated with similar survival in high-risk localized prostate cancer","volume":"36","author":"Ennis","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102717_bib2065","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason Score 9-10 Prostate Cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2075","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib2080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijrobp.2017.02.027","article-title":"ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2085","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.brachy.2018.12.007","article-title":"A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer","volume":"18","author":"King","year":"2019","journal-title":"Brachytherapy"},{"issue":"1\u20132","key":"10.1016\/j.fjurol.2024.102717_bib2090","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.canrad.2021.11.017","article-title":"External radiotherapy for prostatic cancers","volume":"26","author":"de Crevoisier","year":"2022","journal-title":"Cancer Radiother"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib2095","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs. computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE Randomized Clinical Trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"15","key":"10.1016\/j.fjurol.2024.102717_bib2100","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC Trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib2105","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib2110","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0360-3016(95)00063-5","article-title":"Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone","volume":"32","author":"Shipley","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib2115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M.D.\u00a0Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102717_bib2120","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1200\/JCO.2009.25.8475","article-title":"Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group\/american college of radiology 95-09","volume":"28","author":"Zietman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.fjurol.2024.102717_bib2125","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68\u00a0Gy of radiotherapy with 78\u00a0Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib2130","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70\u00a0Gy versus 80\u00a0Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.fjurol.2024.102717_bib2135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2020.10.023","article-title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial","volume":"143","author":"Nabid","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib2140","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2022.04.003","article-title":"High-dose radiotherapy or androgen deprivation therapy (HEAT) as treatment intensification for localized prostate cancer: an individual patient-data network meta-analysis from the MARPCA Consortium","volume":"82","author":"Kishan","year":"2022","journal-title":"Eur Urol"},{"issue":"31","key":"10.1016\/j.fjurol.2024.102717_bib2145","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102717_bib2150","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.fjurol.2024.102717_bib2155","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102717_bib2160","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.fjurol.2024.102717_bib2165","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.canrad.2017.11.004","article-title":"Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: the French genito-urinary group (GETUG) recommendations","volume":"22","author":"Langrand-Escure","year":"2018","journal-title":"Cancer Radiother"},{"issue":"10196","key":"10.1016\/j.fjurol.2024.102717_bib2175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib2180","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102717_bib2185","doi-asserted-by":"crossref","first-page":"103661","DOI":"10.1016\/j.critrevonc.2022.103661","article-title":"Highly hypofractionated schedules for localized prostate cancer: recommendations of the GETUG radiation oncology group","volume":"173","author":"Lapierre","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"34","key":"10.1016\/j.fjurol.2024.102717_bib2190","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1200\/JCO.2006.10.5171","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01","volume":"25","author":"Pommier","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib2195","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib2200","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrurol.2015.50","article-title":"Synergistic action of image-guided radiotherapy and androgen deprivation therapy","volume":"12","author":"Locke","year":"2015","journal-title":"Nat Rev Urol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib2205","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib2210","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijrobp.2018.07.2006","article-title":"Daily versus weekly prostate cancer image guided radiation therapy: phase 3 multicenter randomized trial","volume":"102","author":"de Crevoisier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib2215","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijrobp.2011.05.058","article-title":"Improving positioning in high-dose radiotherapy for prostate cancer: safety and visibility of frequently used gold fiducial markers","volume":"83","author":"Fonteyne","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib2220","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib2225","doi-asserted-by":"crossref","first-page":"e208221","DOI":"10.1001\/jamanetworkopen.2020.8221","article-title":"Association of the placement of a perirectal hydrogel spacer with the clinical outcomes of men receiving radiotherapy for prostate cancer: a systematic review and meta-analysis","volume":"3","author":"Miller","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib2230","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2013.04.039","article-title":"Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients","volume":"65","author":"Crouzet","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib2235","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1464-410X.2012.11715.x","article-title":"Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer","volume":"112","author":"Ganzer","year":"2013","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2240","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.juro.2013.02.010","article-title":"Evolution and outcomes of 3\u00a0MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years","volume":"190","author":"Thuroff","year":"2013","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib2245","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1464-410X.2011.10251.x","article-title":"Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer","volume":"108","author":"Boutier","year":"2011","journal-title":"BJU Int"},{"issue":"49","key":"10.1016\/j.fjurol.2024.102717_bib2250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19490","article-title":"Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation","volume":"19","author":"Ramsay","year":"2015","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2255","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.euf.2019.11.014","article-title":"High-intensity focused ultrasound for the treatment of prostate cancer: a national cohort study focusing on the development of stricture and fistulae","volume":"7","author":"Dosanjh","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib2260","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.urolonc.2013.04.004","article-title":"Cryotherapy and its applications in the management of urologic malignancies: a review of its use in prostate and renal cancers","volume":"32","author":"Mohammed","year":"2014","journal-title":"Urol Oncol"},{"issue":"13","key":"10.1016\/j.fjurol.2024.102717_bib2265","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/pros.23030","article-title":"A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate","volume":"75","author":"Elshafei","year":"2015","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib2270","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.juro.2009.05.041","article-title":"Primary cryoablation nadir prostate specific antigen and biochemical failure","volume":"182","author":"Levy","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102717_bib2275","article-title":"Detailing sexual outcomes after focal therapy for localised prostate cancer: a systematic review and meta-analysis","author":"Fiard","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib2280","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1172\/JCI70354","article-title":"Tracking the clonal origin of lethal prostate cancer","volume":"123","author":"Haffner","year":"2013","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib2285","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2014.10.026","article-title":"Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review","volume":"68","author":"Valerio","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib2290","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/pcan.2017.8","article-title":"Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project","volume":"20","author":"Tay","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib2295","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2018.01.001","article-title":"Focal therapy in primary localised prostate cancer: the European Association of Urology Position in 2018","volume":"74","author":"van der Poel","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib2300","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?","volume":"81","author":"Hopstaken","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2305","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2016.09.039","article-title":"Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients","volume":"71","author":"Rischmann","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib2310","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bju.15004","article-title":"Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry","volume":"125","author":"Lovegrove","year":"2020","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib2315","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","article-title":"A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer","volume":"74","author":"Guillaumier","year":"2018","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib2320","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1464-410X.2011.10578.x","article-title":"Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry","volume":"109","author":"Ward","year":"2012","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2325","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(16)30661-1","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial","volume":"18","author":"Azzouzi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2330","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2012.05.011","article-title":"Focal therapy of prostate cancer: energies and procedures","volume":"31","author":"Bozzini","year":"2013","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib2335","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/bju.14951","article-title":"Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment","volume":"125","author":"Blazevski","year":"2020","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib2340","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.clon.2021.10.012","article-title":"Comparative effectiveness analyses of salvage prostatectomy and salvage radiotherapy outcomes following focal or whole-gland ablative therapy (high-intensity focused ultrasound, cryotherapy or electroporation) for localised prostate cancer","volume":"34","author":"Nathan","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib2345","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102717_bib2350","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/cncr.28609","article-title":"The likelihood of death from prostate cancer in men with favourable or unfavourable intermediate-risk disease","volume":"120","author":"Keane","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib2355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/pcan.2016.51","article-title":"Active surveillance for intermediate-risk prostate cancer","volume":"20","author":"Dall\u2019Era","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib2360","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.juro.2016.06.102","article-title":"Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook Experience","volume":"196","author":"Musunuru","year":"2016","journal-title":"J Urol"},{"issue":"15","key":"10.1016\/j.fjurol.2024.102717_bib2365","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib2370","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2013.02.025","article-title":"Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial","volume":"64","author":"Bill-Axelson","year":"2013","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib2375","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs. radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D\u2019Amico","year":"2008","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2380","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102717_bib2385","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib2390","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.eururo.2023.01.020","article-title":"Effects of androgen deprivation therapy on prostate cancer outcomes according to competing event risk: secondary analysis of a phase 3 randomised trial","volume":"85","author":"Mell","year":"2024","journal-title":"Eur Urol"},{"issue":"27","key":"10.1016\/j.fjurol.2024.102717_bib2395","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.21.00855","article-title":"Short androgen suppression and radiation dose escalation in prostate cancer: 12-year results of EORTC Trial 22991 in patients with localized intermediate-risk disease","volume":"39","author":"Bolla","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2400","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib2405","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.22.00970","article-title":"Sequencing of androgen-deprivation therapy of short duration with radiotherapy for nonmetastatic prostate cancer (SANDSTORM): a pooled analysis of 12 randomized trials","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102717_bib2410","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300023","article-title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","volume":"2","author":"Spratt","year":"2023","journal-title":"NEJM Evid"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102717_bib2415","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2014.01.020","article-title":"Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study","volume":"67","author":"Joniau","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib2420","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.ijrobp.2011.04.037","article-title":"Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease","volume":"81","author":"Stenmark","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102717_bib2425","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib2430","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.ijrobp.2009.10.007","article-title":"Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31","volume":"78","author":"Souhami","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"10.1016\/j.fjurol.2024.102717_bib2435","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1200\/JCO.2014.57.7510","article-title":"Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer","volume":"33","author":"Mason","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib2440","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.eururo.2016.03.021","volume":"70","author":"Fossa","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2445","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","volume":"20","author":"Denham","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib2450","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib2455","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102717_bib2460","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.fjurol.2024.102717_bib2465","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.25900","article-title":"Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer","volume":"117","author":"Boorjian","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.fjurol.2024.102717_bib2470","doi-asserted-by":"crossref","first-page":"g1502","DOI":"10.1136\/bmj.g1502","article-title":"Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes","volume":"348","author":"Sooriakumaran","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib2475","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.clgc.2014.01.010","article-title":"Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Petrelli","year":"2014","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib2480","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib2485","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4103\/aja.aja_96_20","article-title":"Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Liu","year":"2021","journal-title":"Asian J Androl"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102717_bib2490","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10024","key":"10.1016\/j.fjurol.2024.102717_bib2495","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.fjurol.2024.102717_bib2500","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 Trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.fjurol.2024.102717_bib2505","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102717_bib2510","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.03.031","article-title":"Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavourable prostate cancer: a systematic review and meta-analysis","author":"Rajwa","year":"2022","journal-title":"Eur Urol"},{"issue":"10323","key":"10.1016\/j.fjurol.2024.102717_bib2515","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib2520","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2525","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eururo.2012.03.053","article-title":"Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial","volume":"62","author":"Mottet","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib2530","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.euo.2019.02.001","article-title":"A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer","volume":"2","author":"Ventimiglia","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102717_bib2535","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2017.08.011","article-title":"Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis","volume":"73","author":"Seisen","year":"2018","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102717_bib2540","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cDocetaxel Era\u201d: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102717_bib2545","first-page":"279","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE Trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102717_bib2550","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.euo.2018.09.015","article-title":"Association between radical prostatectomy and survival in men with clinically node-positive prostate cancer","volume":"2","author":"Sarkar","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102717_bib2555","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024001748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024001748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T04:00:11Z","timestamp":1732248011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393024001748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":312,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2950393024001748"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102717","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2024\u20132026: Prostate cancer\u00a0\u2013\u00a0Diagnosis and management of localised disease","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102717"}}